Gene therapy is a relatively novel field that amounts to around four decades of continuous growth with its good and bad moments. Currently, the field has entered the clinical arena with the ambition to fulfil its promises for a permanent fix of incurable genetic disorders. Hemoglobinopathies as target diseases and hematopoietic stem cells (HSCs) as target cells of genetic interventions had a major share in the research effort toward efficiently implementing gene therapy. Dissection of HSC biology and improvements in gene transfer and gene expression technologies evolved in an almost synchronous manner to a point where the two fields seem to be functionally intercalated. In this review, we focus specifically on the development of gene therapy for hemoglobin disorders and look at both gene addition and gene correction strategies that may dominate the field of HSC-directed gene therapy in the near future and transform the therapeutic landscape for genetic diseases.
Get full access to this article
View all access options for this article.
References
1.
DzierzakEA, PapayannopoulouT, MulliganRC. Lineage-specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature, 1988; 331:35–41.
2.
MiyoshiH, SmithKA, MosierDE, et al.Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science, 1999; 283:682–686.
3.
NaldiniL, BlömerU, GallayP, et al.In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 1996; 272:263–267.
4.
JosephsonNC, VassilopoulosG, TrobridgeGD, et al.Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci U S A, 2002; 99:8295–8300.
5.
VassilopoulosG, RethwilmA. Foamy virus vectors: the usefulness of a perfect parasite. Gene Ther, 2008; 15:1299–1301.
6.
AiutiA, SlavinS, AkerM, et al.Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 2002; 296:2410–2413.
7.
Hacein-Bey-AbinaS, Le DeistF, CarlierF, et al.Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med, 2002; 346:1185–1193.
8.
Hacein-Bey-AbinaS, Von KalleC, SchmidtM, et al.LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003; 302:415–419.
9.
OttM, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 12:401–409.
10.
BraunC, BoztugK, ParuzynskiA, et al.Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med, 2014; 6:227ra33.
11.
WuX, LiY, CriseB, et al.Transcription start regions in the human genome are favored targets for MLV integration. Science, 2003; 300:1749–1751.
12.
SchröderA, ShinnP, ChenH, et al.HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002; 110:521–529.
13.
TrobridgeGD, MillerDG, JacobsMA, et al.Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A, 2006; 103:1498.
14.
RoeT, ReynoldsTC, YuG, et al.Integration of murine leukemia virus DNA depends on mitosis. EMBO J, 1993; 12:2099.
15.
TrobridgeG, RussellDW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol, 2004; 78:2327–2335.
16.
AngelucciE, Matthes-MartinS, BaroncianiD, et al.Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica, 2014; 99:811–820.
17.
PersonsD.The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in beta-thalassemia patients. Ann N Y Acad Sci, 2010; 1202:69–74.
18.
HanJ, TamK, MaF, et al.β-globin lentiviral vectors have reduced titers due to incomplete vector RNA genomes and lowered virion production. Stem Cell Reports, 2020; 16:198–211.
19.
TalbotD, CollisP, AntoniouM, et al.A dominant control region from the human beta-globin locus conferring integration site-independent gene expression. Nature, 1989; 338:352–355.
20.
YannakiE, KarponiG, ZervouF, et al.Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte–colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum Gene Ther, 2013; 24:852.
21.
Lagresle-PeyrouC, LefrèreF, MagrinE, et al.Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica, 2018; 103:778–786.
22.
Cavazzana-CalvoM, FischerA, Hacein-Bey-AbinaS, et al.Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol, 2012; 24:580–584.
23.
Hacein-Bey-AbinaS, GarrigueA, WangGP, et al.Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 2008; 118:3132.
24.
CesanaD, RanzaniM, VolpinM, et al.Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther, 2014; 22:774.
25.
MayC, RivellaS, CallegariJ, et al.Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature, 2000; 406:82–86.
26.
PawliukR, WestermanK, FabryM, et al.Correction of sickle cell disease in transgenic mouse models by gene therapy. Science, 2001; 294:2368–2371.
27.
MiccioA, CesariR, LottiF, et al.In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A, 2008; 105:10547–10552.
28.
PestinaT, HargroveP, JayD, et al.Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther, 2009; 17:245–252.
29.
PuthenveetilG, ScholesJ, CarbonellD, et al.Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood, 2004; 104:3445–3453.
30.
ChungJ, WhiteleyM, FelsenfeldG. A 5’ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell, 1993; 74:505–514.
31.
EmeryD, YannakiE, TubbJ, et al.A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci U S A, 2000; 97:9150–9155.
32.
UchidaN, WashingtonK, LapC, et al.Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. Mol Ther, 2011; 19:133–139.
33.
LiuM, MauranoMT, WangH, et al.Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol, 2015; 33:198–203.
34.
PapayanniPG, PsathaN, ChristofiP, et al. Investigating the barrier activity of novel, human enhancer-blocking chromatin insulators for hematopoietic stem cell gene therapy. Hum Gene Ther 2021 [Epub ahead of print]; DOI: 10.1089/hum.2021.142. PMID: 34477013.
35.
Cavazzana-CalvoM, PayenE, NegreO, et al.Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 2010; 467:318–322.
36.
ThompsonA, WaltersM, KwiatkowskiJ, et al.Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med, 2018; 378:1479–1493.
37.
YannakiE, LocatelliF, KwiatkowskiJL, et al.Betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent β-thalassemia: updated long-term efficacy and safety results. Hemasphere, 2021; 5:S2.
38.
MarktelS, ScaramuzzaS, CicaleseM, et al.Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med, 2019; 25:234–241.
39.
BouladF, WangX, QuJ, et al.Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood, 2014; 123:1483–1486.
40.
BouladF, Mansilla-SotoJ, CabrioluA, et al.Gene therapy and genome editing. Hematol Oncol Clin North Am, 2018; 32:329–342.
41.
TisdaleJ, PiercieyF, BonnerM, et al.Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. Am J Hematol, 2020; 95:E239–E242.
42.
ThompsonAA, WaltersMC, MaparaMY, et al.Resolution of serious vaso-occlusive pain crises and reduction in patient-reported pain intensity: results from the ongoing phase 1/2 HGB-206 Group C Study of LentiGlobin for sickle cell disease (bb1111) gene therapy. Blood, 2020; 136:16–17.
43.
HsiehMM, BonnerM, PiercieyFJ, et al.Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv, 2020; 4:2058.
44.
GrimleyM, AsnaniM, ShresthaA, et al.Early results from a phase 1/2 Study of Aru-1801 gene therapy for sickle cell disease (SCD): manufacturing process enhancements improve efficacy of a modified gamma globin lentivirus vector and reduced intensity conditioning transplant. Blood, 2020; 136:20–21.
45.
EsrickE, LehmannL, BiffiA, et al.Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med, 2021; 384:205–215.
46.
RichterM, SaydaminovaK, YumulR, et al.In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. Blood, 2016; 128:2206–2217.
47.
WangH, GeorgakopoulouA, PsathaN, et al.In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest, 2019; 129:598–615.
48.
RajawatYS, HumbertO, CookSM, et al.In vivo gene therapy for canine SCID-X1 using cocal-pseudotyped lentiviral vector. Hum Gene Ther, 2021; 32:113–127.
49.
ShivramH, CressB, KnottG, et al.Controlling and enhancing CRISPR systems. Nat Chem Biol, 2021; 17:10–19.
50.
SongM, KooT. Recent advances in CRISPR technologies for genome editing. Arch Pharm Res, 2021; 44:537–552.
51.
KimS, KooT, JeeH, et al.CRISPR RNAs trigger innate immune responses in human cells. Genome Res, 2018; 28:367–373.
52.
KonialiL, LedererC, KleanthousM. Therapy development by genome editing of hematopoietic stem cells. Cells, 2021; 10:1492.
53.
AnurogoD, BudiYP, Nhi NgoM, et al.Cell and gene therapy for anemia: hematopoietic stem cells and gene editing. Int J Mol Sci, 2021; 22:6275.
54.
Gutierrez-GuerreroA, CossetF, VerhoeyenE. Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy. Viruses, 2020; 12:1016.
55.
DrakopoulouE, GeorgomanoliM, LedererC, et al.A novel BaEVRless-pseudotyped γ-globin lentiviral vector drives high and stable fetal hemoglobin expression and improves thalassemic erythropoiesis in vitro. Hum Gene Ther, 2019; 30:601–617.
56.
IolasconA, RivellaS, AnagnouNP, et al.The EHA research roadmap: anemias. Hemasphere, 2021; 5:e607.
57.
DeWittM, MagisW, BrayN, et al.Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 2016; 8:360ra134.
58.
WilkinsonA, DeverD, BaikR, et al.Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nat Commun, 2021; 12:686.
59.
PatsaliP, TurchianoG, PapasavvaP, et al.Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells. Haematologica, 2019; 104:E497–E501.
60.
XuS, LukK, YaoQ, et al.Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. Blood, 2019; 133:2255–2262.
61.
NewbyG, YenJ, WoodardK, et al.Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature, 2021; 595:295–302.
62.
FessasP, StamatoyannopoulosG. Hereditary persistence of fetal hemoglobin in Greece. A study and a comparison. Blood, 1964; 24:223–240.
63.
SankaranV, MenneT, XuJ, et al.Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science, 2008; 322:1839–1842.
64.
BauerD, KamranS, LessardS, et al.An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science, 2013; 342:253–257.
65.
VierstraJ, ReikA, ChangK, et al.Functional footprinting of regulatory DNA. Nat Methods, 2015; 12:927–930.
66.
CanverM, SmithE, SherF, et al.BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015; 527:192–197.
67.
LiC, PsathaN, WangH, et al.Integrating HDAd5/35++ vectors as a new platform for HSC gene therapy of hemoglobinopathies. Mol Ther Methods Clin Dev, 2018; 9:142–152.
68.
PsathaN, ReikA, PhelpsS, et al.Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major. Mol Ther Methods Clin Dev, 2018; 10:313–326.
69.
UrnovFD, ReikA, VierstraJ, et al.Clinical-scale genome editing of the human BCL11A erythroid enhancer for treatment of the hemoglobinopathies. Blood, 2015; 126:204.
70.
DemirciS, ZengJ, WuY, et al.BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity. J Clin Invest, 2020; 130:6677–6687.
71.
Sangamo, Sanofi Show Positive Early Data for SCD Gene-Edited Cell Therapy https://www.genengnews.com/news/sangamo-sanofi-show-positive-early-data-for-scd-gene-edited-cell-therapy/ (last accessed August2, 2021).
72.
FrangoulH, AltshulerD, CappelliniM, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med, 2021; 384:252–260.
73.
LocatelliF. CTX001 FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA: SAFETY AND… EHALibrary. June 9, 2021; 325492. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325492/franco.locatelli.ctx001.for.transfusion-dependent.-thalassemia.safety.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dctx001 (last accessed August2, 2021).
74.
VinjamurD, YaoQ, ColeM, et al.ZNF410 represses fetal globin by singular control of CHD4. Nat Genet, 2021; 53:719–728.
75.
AntonianiC, MeneghiniV, LattanziA, et al.Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood, 2018; 131:1960–1973.
76.
MartynG, WienertB, YangL, et al.Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet, 2018; 50:498–503.
77.
TraxlerE, YaoY, WangY, et al.A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med, 2016; 22:987–990.
78.
HumbertO, RadtkeS, SamuelsonC, et al.Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. Sci Transl Med, 2019; 11:eaaw3768.
79.
MingoiaM, CariaC, YeL, et al.Induction of therapeutic levels of HbF in genome-edited primary β 0 39-thalassaemia haematopoietic stem and progenitor cells. Br J Haematol, 2021; 192:395–404.
80.
PsathaN, GeorgakopoulouA, LiC, et al. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood 2021 [Epub ahead of print]; DOI: 10.1182/BLOOD.2020010020.
81.
LiC, GeorgakopoulouA, MishraA, et al.In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice. Blood Adv, 2021; 5:1122–1135.
82.
BrunsonA, KeeganT, BangH, et al.Increased risk of leukemia among sickle cell disease patients in California. Blood, 2017; 130:1597–1599.
83.
GhannamJ, XuX, MaricI, et al.Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood, 2020; 135:1185–1188.
84.
HankinsJ, AygunB, NottageK, et al.From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore), 2014; 93:e215.
85.
LiY, MauleJ, NeffJ, et al.Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod Pathol, 2019; 32:1712–1726.
86.
ArumugamP, HigashimotoT, UrbinatiF, et al.Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther, 2009; 17:1929–1937.
EmeryD, YannakiE, TubbJ, et al.Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood, 2002; 100:2012–2019.
89.
Maggio Α, SadelainM, RiviereI, et al. Gene therapy with the lentiviral vector TNS9.3.55 produces long-term improvement in severe ß thalassemia. https://library.ehaweb.org/eha/2020/eha25th/293982/simona.raso.gene.the rapy.with.the.lentiviral.vector.tns9.3.55.produces.html (last accessed December6, 2020).
90.
WongT, RamsinghG, YoungA, et al.Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015; 518:552–555.
91.
ChhabrA, RingA, WeiskopfK, et al.Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med, 2016; 8:351ra105.
92.
PalchaudhuriR, SaezB, HoggattJ, et al.Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol, 2016; 34:738–745.
93.
LiC, PsathaN, GilS, et al.HDAd5/35 ++ adenovirus vector expressing anti-CRISPR peptides decreases CRISPR/Cas9 toxicity in human hematopoietic stem cells. Mol Ther Methods Clin Dev, 2018; 9:390–401.
94.
LiC, PsathaN, SovaP, et al.Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing. Blood, 2018; 131:2915–2928.
95.
LiC, WangH, GeorgakopoulouA, et al.In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model. Mol Ther, 2021; 29:822–837.
96.
ChangL, HongjieW, SucheolG, et al.In vivo HSC gene therapy for hemoglobinopathies: a proof of concept evaluation in rhesus macaques. Blood, 2020; 136:46–47.
